A/Prof Tim Clay (@drtclay) header
A/Prof Tim Clay (@drtclay) profile picture

A/Prof Tim Clay

@drtclay

Medical oncologist from Perth - Australia. Interested in thoracic oncology, breast cancer, GUs, clinical trials, fast cars (Formula 1) and @werderbremen_en

 Perth, Western Australia
drtimclay.com.au
Joined March 2013
  • Tweets5.8K
  • Following1.5K
  • Followers1.7K
928Media
Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)Photo by A/Prof Tim Clay (@drtclay)
A/Prof Tim Clay retweeted
KRAS Kickers (@KRASKickers) profile picture
KRAS Kickers
@KRASKickersSep 9
TARGET-D 201 A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy & W/ Cetuximab, in Patients W/ Metastatic KRAS G12D-Mutated Pancreatic Cancer Opened June 26 180 ps 29 locations: US, Canada & Australia NCT07644559 facebook.com/permalink.php?s…
Image from KRAS Kickers (@KRASKickers)
1
5
16
1,167
👀 WCLC 2026: studies not to miss @IASLC My selection of the must-see studies at #WCLC26 - the abstracts and presentations worth keeping on your radar throughout the meeting. 📌 Save these for your WCLC agenda!
Image from Diego A. Díaz-García (@diegoadiazg)
Image from Diego A. Díaz-García (@diegoadiazg)
Image from Diego A. Díaz-García (@diegoadiazg)
20
32
2,784
A/Prof Tim Clay retweeted
Neil Stone (@DrNeilStone) profile picture
Neil Stone
@DrNeilStoneJun 1
My home country Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 NO cervical cancer cases detected in vaccinated women following HPV immunisation! None! Zero! What a stunning achievement ! The HPV vaccine ie a modern medical miracle!
Image from Neil Stone (@DrNeilStone)
353
3,528
115
13,584
218,975
A/Prof Tim Clay retweeted
Matthew Herper (@matthewherper) profile picture
Matthew Herper
@matthewherperMay 31
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously. Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here. This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group. If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
Image from Matthew Herper (@matthewherper)
44
425
38
2,298
295,952
What an interrupting standing #ovation looks like from the front of #ASCO26 when a revolution in science comes for #pancsm treatment #GIonc.
2
38
2
252
15,923
A/Prof Tim Clay retweeted
Mark Lewis, MD, FASCO (@marklewismd) profile picture
Mark Lewis, MD, FASCO
@marklewismdMay 31
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26
92
1,257
213
6,471
1,185,569
A/Prof Tim Clay retweeted
Mark Lewis, MD, FASCO (@marklewismd) profile picture
Mark Lewis, MD, FASCO
@marklewismdMay 31
As many other oncologists will also attest, we were taught this was a dead end It was, dogmatically, never going to work — kras was too much of a “greasy ball” to be targeted And yet here we are, with truly meaningful survival curves👇 Inspiration on multiple levels #ASCO26
Image from Mark Lewis, MD, FASCO (@marklewismd)
Dr. Catharine Young (@DrCatharineY) profile pictureDr. Catharine Young
@DrCatharineYMay 31
What I love about this news is that this is not simply a new pancreatic cancer drug. It’s that KRAS, one of cancer biology’s most notorious undruggable targets, has finally become druggable. A powerful reminder that persistence in science can eventually unlock the impossible.
17
169
10
1,083
91,271
This is a moral issue for the oncology community. Were a drug or supportive care intervention to show OS curves like this, it would be SOC, and covered. For far less than costs of new drugs, our society could provide food for our patients. Perhaps our clinics need to do that.
Yara Abdou, MD, MSCR (@YAbdouMD) profile pictureYara Abdou, MD, MSCR
@YAbdouMDMay 31
Food insecurity is not just a social issue — it is a cancer outcomes issue‼️ Pts with MBC living in food deserts had distinct genomic profiles, including higher rates of RTK/RAS pathway alterations and CCNE1 copy number variants, along w/ worse survival outcomes — particularly among Black pts. A powerful reminder that biology and structural inequities are deeply intertwined. #HealthEquity #ASCO2026 @OncoAlert
Image from Yara Abdou, MD, MSCR (@YAbdouMD)
6
30
89
14,938
A/Prof Tim Clay retweeted
Stephen V Liu, MD (@StephenVLiu) profile picture
Stephen V Liu, MD
@StephenVLiuMay 29
Dr. Caicun Zhou at #ASCO26 with results from phase III OptiTROP-Lung05: first-line sacituzumab govitecan (sac-TMT, TROP2 ADC) + pembro vs pembro for PD-L1+ NSCLC (n=413). Sac-TMT superior with PFS NR vs 6.6m (HR 0.38) with benefit across subgroups.
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
4
39
6
93
32,191
A/Prof Tim Clay retweeted
Dr Riyaz Shah (@DrRiyazShah) profile picture
Dr Riyaz Shah@DrRiyazShahMay 22
It’s astonishing that CROWN 7y update shows mPFS and median time to IC PFS are still NOT REACHED: Surprisingly only 34% needed a DR and 5% TRAE>discontinuation. Current 4th gen trials will be criticised for inadequate control arms. #ASCO26 @ALKpositiveINT @BTOGORG
Image from Dr Riyaz Shah (@DrRiyazShah)
Image from Dr Riyaz Shah (@DrRiyazShah)
1
4
8
858
Impressive data on #nextgen #KRAS G12C inhibitor, Elisrasib, at #AACR26. ORR 73.5% with durable responses to >= 3y in treatment naive population! #LCSM @yonsei_u
LUNGevity Foundation (@LUNGevity) profile pictureLUNGevity Foundation
@LUNGevityApr 19
Exciting data presented by @cbcbc1971 @yonsei_u on elisrasib (D3S-001), a next-gen KRAS G12C inhibitor in advanced #NSCLC: ➡️G12Ci-naïve: Observed response rate 73.5%, with durable responses seen out to 3+ years ➡️G12Ci-refractory (600mg QD): ORR ~31%, with 8 pts (25%) still on treatment ⚡ 70% of responders achieved first response by Week 6. Elisrasib received BTD & Fast Track Designation for #NSCLC by @US_FDA. A promising option in both treatment-naïve & post-G12Ci settings @KRASKickers #lcsm #AACR26
Image from LUNGevity Foundation (@LUNGevity)
1
3
4
612
A/Prof Tim Clay retweeted
Stephen V Liu, MD (@StephenVLiu) profile picture
Stephen V Liu, MD
@StephenVLiuApr 20
Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor.
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
7
54
6
142
24,375
A/Prof Tim Clay retweeted
Stephen V Liu, MD (@StephenVLiu) profile picture
Stephen V Liu, MD
@StephenVLiuApr 20
#AACR26 Zoldonrasib in previously treated KRAS G12D NSCLC with RR 52%, DCR 93%, time to response 1.4m, mDOR not reached with median follow up of 13.1m, mPFS 11.1m, and 73% of pts with ctDNA clearance. Fantastic presentation, exciting drug for our patients!
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
1
13
5
43
15,323
🎧️ NEW EPISODE TOMORROW Our host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Tune in Friday, April 10th, at 8am.
Image from Thoracic Oncology Group of Australasia (@TOGAANZ)
2
1
9
194
A/Prof Tim Clay retweeted
Uğur Özkerim (@UOzkerim) profile picture
Uğur Özkerim
@UOzkerimApr 5
👀Not all KRAS mutations behave the same. 🧬KRAS G12V shows a clear smoking-driven profile (94% smokers) with frequent TP53/STK11/KEAP1 co-mutations—yet still derives benefit from PD-1 blockade, particularly in PD-L1 high disease (rwOS ~30 months). Not the “IO-resistant” story we expected✅ @OncoAlert @OncoReporte @MedwatchKate @ManuelDomine @lung_connect @MedicalwatchHQ
Image from Uğur Özkerim (@UOzkerim)
2
42
137
9,530
A/Prof Tim Clay retweeted
Charles Swanton (@CharlesSwanton) profile picture
Charles Swanton@CharlesSwantonApr 5
People often ask how breakthroughs occur in cancer biology-often the story is more complex - the survival plot for myeloma outcomes is extraordinary - improvements come about in incremental steps - in my lifetime treatment of Myeloma has almost transformed into a curable disease
Image from Charles Swanton (@CharlesSwanton)
25
256
29
1,006
205,897
A/Prof Tim Clay retweeted
Oscar Tahuahua (@drtahuahua) profile picture
Oscar Tahuahua
@drtahuahuaApr 1
KRASG12C inhibition meets EGFR feedback Block both KROCUS trial. Fulzerasib + cetuximab in 1L NSCLC (phase 1b/2) in @TheLancetOncol ORR 69%, PFS 12.5 mo Rational combination. Promising early signal thelancet.com/journals/lanon… @OncoAlert
Image from Oscar Tahuahua (@drtahuahua)
Oscar Tahuahua (@drtahuahua) profile pictureOscar Tahuahua
@drtahuahuaMar 17
We thought KRAS was the engine So it was turned off But tumors adapt, rerouting the pathway In this preclinical study in KRASm NSCLC, loss of PTPRR activates EGFR, reactivating ERK and driving resistance to sotorasib/adagrasib. KRAS is blocked EGFR turns the pathway back on That’s why vertical blockade (KRAS + EGFR) may matter, remember that preclinical study 🇪🇸 ❓ Will panRAS inhibitors be enough? Preclinical data suggest probably not. Combos may be the answer aacrjournals.org/cancerresco… @OncoAlert @Aiims1742
Image from Oscar Tahuahua (@drtahuahua)
Image from Oscar Tahuahua (@drtahuahua)
Image from Oscar Tahuahua (@drtahuahua)
24
1
67
9,494
A/Prof Tim Clay retweeted
Samuel Hume (@DrSamuelBHume) profile picture
Samuel Hume
@DrSamuelBHumeMar 28
How EGFR inhibitors transformed outcomes in EGFR-mutated non–small-cell lung cancer
Image from Samuel Hume (@DrSamuelBHume)
11
91
6
340
31,066
A/Prof Tim Clay retweeted
Javier Puente (@docjavip) profile picture
Javier Puente@docjavipFeb 27
KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem: 🔥 47% reduction in risk of events (HR 0.53) 🔥 Significant OS benefit (HR 0.65) 🔥 pCR 55.8% vs 32.5% A true paradigm shift for cisplatin-eligible MIBC. Honored to be part of this milestone with our HCSC team #GU26
Image from Javier Puente (@docjavip)
Image from Javier Puente (@docjavip)
Image from Javier Puente (@docjavip)
Image from Javier Puente (@docjavip)
3
21
1
55
5,014
A/Prof Tim Clay retweeted
Neil Stone (@DrNeilStone) profile picture
Neil Stone
@DrNeilStoneJan 24
My home country Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 NO cervical cancer cases detected in vaccinated women following HPV immunisation! None! Zero! What a stunning achievement ! The HPV vaccine ie a modern medical miracle!
Image from Neil Stone (@DrNeilStone)
216
2,415
117
10,649
570,278
Load more